<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444752</url>
  </required_header>
  <id_info>
    <org_study_id>CBP-201-WW001</org_study_id>
    <nct_id>NCT04444752</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of CBP-201</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Connect Biopharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Connect Biopharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of&#xD;
      CBP-201 in adult subjects with moderate to severe atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose regimen finding study to assess&#xD;
      the efficacy, safety, and steady-state PK profile of CBP-201 administered to eligible adult&#xD;
      subjects with moderate to severe atopic dermatitis compared to placebo. CBP-201 is&#xD;
      administered as a subcutaneous (SC) injection. The study is divided into a treatment period&#xD;
      of 16 weeks and a follow-up period of 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema area and severity index (EASI) percentage change (EASI-overall)</measure>
    <time_frame>From Baseline to Week 16</time_frame>
    <description>Percentage change in EASI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AE)</measure>
    <time_frame>From Screen (Day-45) until end of study at Week 24</time_frame>
    <description>Safety will be assessed on basis of AEs reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Steady-state trough PK profile)</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Whole blood for plasma CBP-201 concentrations will be obtained and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of IL-4</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in serum levels of IL-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of IL-13</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in serum levels of IL-13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of IgE</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in serum levels of IgE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole blood eosinophil counts</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Changes from Baseline will be summarized with descriptive statistics in whole blood eosinophil counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>At Week 16</time_frame>
    <description>Proportion of subjects with IGA 0-1 and a reduction of ≥2 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-50</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <description>Proportion of subjects achieving ≥ 50% reduction of EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-75</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <description>Proportion of subjects achieving ≥ 75% reduction of EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-90</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <description>Proportion of subjects achieving ≥ 90% reduction of EASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Pruritus Numerical Rating Scale(PP-NRS)</measure>
    <time_frame>From Baseline to Week 16</time_frame>
    <description>Percent change from Baseline in weekly average of PP-NRS score to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AD flares</measure>
    <time_frame>From Baseline through Week 16</time_frame>
    <description>Number of AD flares from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with AD flare</measure>
    <time_frame>From Baseline through Week 16</time_frame>
    <description>Number of days with AD flare through Week 16</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Moderate-to-severe Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>CBP-201 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 1 subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBP-201 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 2 subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBP-201 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 Dose 3 subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous (SC) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBP-201</intervention_name>
    <description>CBP-201 subcutaneous(SC) injection.</description>
    <arm_group_label>CBP-201 Dose 1</arm_group_label>
    <arm_group_label>CBP-201 Dose 2</arm_group_label>
    <arm_group_label>CBP-201 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous(SC) injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be an adult ≥18 and ≤ 75 years of age at the screening visit (Screening) with atopic&#xD;
             dermatitis according to American Academy of Dermatology Consensus Criteria,&#xD;
             (Eichenfield 2014)&#xD;
&#xD;
          2. Present for at least 1 year prior to the baseline visit (Baseline) with an inadequate&#xD;
             response, in the judgement of the Investigator, to AD treatment with a topical regimen&#xD;
             of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors, or for&#xD;
             whom topical treatments are otherwise medically inadvisable (eg, because of important&#xD;
             side effect or safety risks)&#xD;
&#xD;
          3. Investigator Global Assessment (IGA) score ≥ 3 at Screening and Baseline.&#xD;
&#xD;
          4. Eczema Area and Severity Index (EASI) score ≥ 16 at Screening and Baseline&#xD;
&#xD;
          5. Body Surface Area (BSA) for total AD involvement ≥ 10% at Screening and Baseline&#xD;
&#xD;
          6. Able and willing to apply a stable dose of a bland emollient twice a day to affected&#xD;
             areas for at least 7 days before Baseline and to continue for the duration of the&#xD;
             study&#xD;
&#xD;
          7. Females of child-bearing potential (FCBP) and males who have not undergone a vasectomy&#xD;
             must abstain from heterosexual activities or agree to use effective contraception&#xD;
             throughout the entire study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have any of the following laboratory abnormalities at Screening:&#xD;
&#xD;
               1. Hemoglobin ≤ 90% of the lower limit of normal range (LLN)&#xD;
&#xD;
               2. White blood cell (WBC) below the LLN&#xD;
&#xD;
               3. Neutrophil count below the LLN&#xD;
&#xD;
               4. Platelet count below the LLN&#xD;
&#xD;
          2. Have undergone treatment with any of the following:&#xD;
&#xD;
               1. Topical agents such as corticosteroids, phosphodiesterase (PDE) inhibitors, Janus&#xD;
                  kinase (JAK) inhibitors, tacrolimus or pimecrolimus within 1 week prior to&#xD;
                  Baseline. Note that low to medium potency topical corticosteroids (TCS) are&#xD;
                  permitted after randomization to treat AD flares&#xD;
&#xD;
               2. Prior treatment with dupilumab or any antibody against IL-4Rα or IL-13&#xD;
&#xD;
               3. Systemic treatment for AD or other condition with steroids or other&#xD;
                  immunosuppressive/immunomodulating substances, e.g., cyclosporine,&#xD;
                  mycophenolate-mofetil, azathioprine, methotrexate or oral Janus kinase (JAK)&#xD;
                  inhibitors within 4 weeks prior to Baseline. Use of steroid inhalers and nasal&#xD;
                  corticosteroids is allowed.&#xD;
&#xD;
               4. Cell depleting agents, e.g. rituximab, within 6 months of Baseline or treatment&#xD;
                  with other biologics within 5 half-lives (if known) or 3 months prior to baseline&#xD;
                  visit, whichever is longer&#xD;
&#xD;
               5. Phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet&#xD;
                  A1 [UVA1], psoralen + ultraviolet A [PUVA]), tanning beds, or any other light&#xD;
                  emitting device (LED), within 4 weeks of Baseline&#xD;
&#xD;
               6. ≥ 2 bleach baths within 2 weeks of Baseline&#xD;
&#xD;
               7. Prescription emollient to treat AD (e.g. Atopiclair®, MimyX®, Epicerum®, etc.)&#xD;
                  within 2 weeks of Baseline&#xD;
&#xD;
               8. Any investigational drug within 30 days or within 5 half-lives, whichever is&#xD;
                  longer, before Baseline.&#xD;
&#xD;
               9. Live (attenuated) vaccine within 8 weeks of Baseline.&#xD;
&#xD;
              10. Treatment with systemic traditional Chinese medicine (TCM) or herbal medications&#xD;
                  within 4 weeks before Baseline or treatment with topical TCM or herbal&#xD;
                  medications within 1 week before Baseline visit&#xD;
&#xD;
          3. Have any of the following:&#xD;
&#xD;
               1. Infection requiring treatment with systemic antibiotics, antivirals,&#xD;
                  antiparasitics, antiprotozoals, or antifungals within 4 weeks before Baseline, or&#xD;
                  superficial skin infection, such as impetigo, within 2 weeks before the Baseline&#xD;
                  (subjects may be rescreened after the infection has resolved)&#xD;
&#xD;
               2. A history of parasitic infection (e.g. helminth), within 6 months of Baseline&#xD;
&#xD;
               3. Per investigator judgement, known or suspected history of immunosuppression&#xD;
                  within 6 months of Baseline, including a history of invasive opportunistic&#xD;
                  infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, human&#xD;
                  immunodeficiency virus (HIV), listeriosis, pneumocystosis, or tuberculosis,&#xD;
                  despite infection resolution; or unusually frequent, recurrent or prolonged&#xD;
                  infections.&#xD;
&#xD;
               4. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis&#xD;
                  (AKC)&#xD;
&#xD;
               5. A history of malignancy with the following exceptions: completely treated&#xD;
                  carcinoma in situ of cervix or non-metastatic squamous or basal cell carcinoma of&#xD;
                  the skin&#xD;
&#xD;
               6. Positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis&#xD;
                  B core antibody (HBcAb) or hepatitis C antibody with positive HCV RNA polymerase&#xD;
                  chain reaction; positive HIV serology at screening&#xD;
&#xD;
               7. An allergy to L-histidine, trehalose or Tween (polysorbate) 80&#xD;
&#xD;
          4. Women must not be pregnant, planning to become pregnant or breast-feed during the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzhou Connect</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Connect Biopharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connect Investigative Site 310</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 338</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 316</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 305</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 327</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 324</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 301</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 312</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 329</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 322</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 323</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 317</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 318</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 325</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 332</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 320</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 306</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 308</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 314</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 331</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 337</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 321</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 304</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 340</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 333</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 303</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 307</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 313</name>
      <address>
        <city>West Lafayette</city>
        <state>Indiana</state>
        <zip>47906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 311</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 319</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 335</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 315</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 336</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 326</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 330</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 328</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 309</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 334</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 111</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 104</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 108</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 105</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2289</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 101</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 102</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 106</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 103</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 408</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 404</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 405</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 409</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 402</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 401</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 406</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 410</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 403</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 204</name>
      <address>
        <city>Tauranga</city>
        <state>Bay Of Plenty</state>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 202</name>
      <address>
        <city>Havelock North</city>
        <state>Hawke's Bay</state>
        <zip>4130</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 205</name>
      <address>
        <city>Waikanae</city>
        <state>Kapiti Coast</state>
        <zip>5036</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connect Investigative Site 203</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

